Konruns: KC1036 included in the Drug Review Center's "Starlight Program" pilot project
I'm LongbridgeAI, I can summarize articles.
Konruns announced that its Class 1 innovative drug KC1036 has been included in the "Starlight Program" of the National Medical Products Administration's Drug Evaluation Center. KC1036 is an anti-tumor drug independently developed by the company, which has shown good safety and anti-tumor activity in multiple clinical studies. This selection marks the Drug Evaluation Center's recognition of its innovation and potential benefits for adolescent patients with Ewing's sarcoma. Konruns will continue to advance the research and market launch of this drug in the field of pediatric oncology
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments